BNP Paribas Financial Markets Increases Stock Position in Henry Schein, Inc. $HSIC

BNP Paribas Financial Markets raised its position in Henry Schein, Inc. (NASDAQ:HSIC) by 18.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 402,534 shares of the company’s stock after buying an additional 62,119 shares during the quarter. BNP Paribas Financial Markets’ holdings in Henry Schein were worth $30,424,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of HSIC. Norges Bank purchased a new stake in shares of Henry Schein during the 4th quarter worth $88,116,000. Eurizon Capital SGR S.p.A. acquired a new position in shares of Henry Schein during the 4th quarter valued at about $1,946,000. Intech Investment Management LLC acquired a new position in shares of Henry Schein during the 4th quarter valued at about $525,000. Clearstead Advisors LLC grew its holdings in shares of Henry Schein by 70.7% during the 4th quarter. Clearstead Advisors LLC now owns 1,681 shares of the company’s stock worth $127,000 after purchasing an additional 696 shares during the period. Finally, Dilation Capital Management LP grew its holdings in shares of Henry Schein by 3.3% during the 4th quarter. Dilation Capital Management LP now owns 79,465 shares of the company’s stock worth $6,006,000 after purchasing an additional 2,545 shares during the period. 96.62% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Henry Schein

In related news, Director Kurt P. Kuehn sold 2,844 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total value of $224,562.24. Following the completion of the transaction, the director owned 15,420 shares in the company, valued at $1,217,563.20. This trade represents a 15.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director William K. Daniel purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $69.19 per share, with a total value of $691,900.00. Following the transaction, the director directly owned 20,000 shares in the company, valued at $1,383,800. This trade represents a 100.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.89% of the stock is currently owned by corporate insiders.

Henry Schein Price Performance

Shares of HSIC opened at $76.30 on Friday. The stock’s fifty day moving average is $74.64 and its 200-day moving average is $75.92. Henry Schein, Inc. has a one year low of $61.94 and a one year high of $89.29. The firm has a market capitalization of $8.69 billion, a price-to-earnings ratio of 23.05, a price-to-earnings-growth ratio of 1.46 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The business had revenue of $3.37 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same quarter last year, the business posted $1.15 earnings per share. The company’s quarterly revenue was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities analysts anticipate that Henry Schein, Inc. will post 5.32 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on HSIC. Mizuho decreased their price target on Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Henry Schein in a research note on Monday, May 4th. UBS Group restated a “neutral” rating and set a $85.00 price objective (down from $87.00) on shares of Henry Schein in a research note on Wednesday, May 6th. Barrington Research set a $97.00 price objective on Henry Schein and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Finally, JPMorgan Chase & Co. increased their target price on Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Henry Schein currently has an average rating of “Hold” and a consensus target price of $86.83.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.